Aclidinium bromide

Not to be confused with Acridinium bromide or Clidinium bromide.

Aclidinium bromide

320px
Systematic (IUPAC) name
[(8R)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-8-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate bromide
Clinical data
Trade names	Bretaris Genuair, Eklira Genuair, Tudorza Pressair
Licence data	US FDA:link
Pregnancy category	US: C (Risk not ruled out)
Legal status	US: ℞-only
Routes of administration	Inhalational
Identifiers
CAS Number	320345-99-1 N
ATC code	R03BB05 (WHO)
PubChem	CID: 11519741
ChemSpider	9694529 N
UNII	UQW7UF9N91 N
KEGG	D08837 Y
ChEBI	CHEBI:65344 N
ChEMBL	CHEMBL551466 N
Chemical data
Formula	C26H30BrNO4S2
Molecular mass	564.55 g·mol−1
SMILES [Br-].O=C(O[C@@H]3C2CC[N+](CCCOc1ccccc1)(CC2)C3)C(O)(c4sccc4)c5sccc5
InChI InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1 N Key:XLAKJQPTOJHYDR-QTQXQZBYSA-M N
NY (what is this?)  (verify)

Aclidinium bromide (INN) is a long-acting, inhaled muscarinic antagonist approved in the US on July 24, 2012 as a maintenance treatment for chronic obstructive pulmonary disease (COPD).

Evidence shows that it can improve quality of life and prevent hospitalization in those with COPD. However, it does not appear to affect the risk of death or the frequency steroids are needed. It is unclear if it differs from the similar medication tiotropium or another commonly used medication class of LAMAs.

Aclidinium is delivered via a multidose dry powder inhaler, the Genuair inhaler.

Brand names

It is marketed under the brand name Tudorza Pressair in the US, Eklira Genuair in the UK, and Tudorza Genuair in Canada; licensed to Menarini under the brand name Bretaris Genuair for majority of EU member states